JP2003505075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003505075A5 JP2003505075A5 JP2001512864A JP2001512864A JP2003505075A5 JP 2003505075 A5 JP2003505075 A5 JP 2003505075A5 JP 2001512864 A JP2001512864 A JP 2001512864A JP 2001512864 A JP2001512864 A JP 2001512864A JP 2003505075 A5 JP2003505075 A5 JP 2003505075A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- composition
- nucleic acid
- sequence
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 63
- 229920001184 polypeptide Polymers 0.000 description 62
- 102000004196 processed proteins & peptides Human genes 0.000 description 62
- 239000000203 mixture Substances 0.000 description 40
- 150000007523 nucleic acids Chemical class 0.000 description 36
- 108020004707 nucleic acids Proteins 0.000 description 33
- 102000039446 nucleic acids Human genes 0.000 description 33
- 238000000034 method Methods 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000002159 abnormal effect Effects 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 230000001594 aberrant effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14589999P | 1999-07-27 | 1999-07-27 | |
| US60/145,899 | 1999-07-27 | ||
| US49458500A | 2000-01-31 | 2000-01-31 | |
| US09/494,585 | 2000-01-31 | ||
| US09/609,543 US7056885B1 (en) | 1999-07-27 | 2000-07-03 | Fibroblast growth factor and nucleic acids encoding same |
| US09/609,543 | 2000-07-03 | ||
| PCT/US2000/020405 WO2001007595A2 (en) | 1999-07-27 | 2000-07-27 | Novel fibroblast growth factor and nucleic acids encoding same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003505075A JP2003505075A (ja) | 2003-02-12 |
| JP2003505075A5 true JP2003505075A5 (enExample) | 2008-02-21 |
Family
ID=46203895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001512864A Pending JP2003505075A (ja) | 1999-07-27 | 2000-07-27 | 新規線維芽細胞増殖因子およびこれをコードする核酸 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7056885B1 (enExample) |
| EP (1) | EP1198563A2 (enExample) |
| JP (1) | JP2003505075A (enExample) |
| AU (1) | AU781980B2 (enExample) |
| CA (1) | CA2380226A1 (enExample) |
| WO (1) | WO2001007595A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7291483B2 (en) | 1999-07-27 | 2007-11-06 | Curagen Corporation | FGF-CX polynucleotide sequences and methods of producing same |
| US7056885B1 (en) | 1999-07-27 | 2006-06-06 | Curagen Corporation | Fibroblast growth factor and nucleic acids encoding same |
| US7253266B2 (en) | 1999-07-27 | 2007-08-07 | Curagen Corporation | Polypeptides of FGF-CX |
| JP2003512841A (ja) * | 1999-10-22 | 2003-04-08 | カイロン コーポレイション | ヒトおよびラットｆｇｆ−２０遺伝子および遺伝子発現産物 |
| US6797695B1 (en) | 1999-10-22 | 2004-09-28 | Kyoto University | Human FGF-20 gene and gene expression products |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| WO2001068854A2 (en) | 2000-03-13 | 2001-09-20 | Amgen, Inc. | Fibroblast growth factor-like molecules and uses thereof |
| GB2365869A (en) * | 2000-05-30 | 2002-02-27 | Smithkline Beecham Corp | SbgFGF-9a polynucleotides and polypeptides |
| WO2001092522A2 (en) * | 2000-06-01 | 2001-12-06 | Eli Lilly And Company | Human fgf-20 nucleic acids and polypeptides |
| IL139380A0 (en) | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
| US6982250B2 (en) | 2000-11-06 | 2006-01-03 | Curagen Corporation | Methods of prevention and treatment of inflammatory bowel disease |
| WO2002058716A2 (en) * | 2000-11-06 | 2002-08-01 | Curagen Corporation | Treatment of inflammatory bowel disease using growth factors |
| US7189693B2 (en) | 2000-11-06 | 2007-03-13 | Curagen Corporation | Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides |
| JP2005500035A (ja) * | 2001-06-15 | 2005-01-06 | キュラジェン コーポレイション | 新規線維芽細胞成長因子およびそれをコード化する核酸 |
| IL149562A0 (en) | 2002-05-09 | 2002-11-10 | Prochon Ltd | Fgf variants and methods for use thereof |
| US7067123B2 (en) | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
| EP1660008A2 (en) * | 2003-05-09 | 2006-05-31 | Curagen Corporation | Therapeutic use of g53135-05(fgf-20) in radiation protection |
| JP2007516223A (ja) * | 2003-05-09 | 2007-06-21 | キュラジェン コーポレイション | 新規線維芽細胞成長因子及びその使用方法 |
| US20050256039A1 (en) * | 2003-05-09 | 2005-11-17 | Jeffery Peterson | Novel fibroblast growth factors and methods of use thereof |
| US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
| WO2006073417A2 (en) * | 2004-05-10 | 2006-07-13 | Curagen Corporation | Prophylactic and therapeutic uses of fgf-20 in radiation protection |
| EP1773372A2 (en) * | 2004-05-10 | 2007-04-18 | Curagen Corporation | Methods of preventing and treating alimentary mucositis |
| WO2005113809A2 (en) * | 2004-05-10 | 2005-12-01 | Curagen Corporation | Novel fibroblast growth factor and nucleic acids encoding same |
| US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
| US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
| WO2007035778A2 (en) | 2005-09-19 | 2007-03-29 | Histogenics Corporation | Cell-support matrix and a method for preparation thereof |
| US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
| US20090054984A1 (en) | 2007-08-20 | 2009-02-26 | Histogenics Corporation | Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects |
| US8685107B2 (en) | 2007-07-03 | 2014-04-01 | Histogenics Corporation | Double-structured tissue implant and a method for preparation and use thereof |
| EP2265220A1 (en) | 2008-03-05 | 2010-12-29 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
| US8870876B2 (en) | 2009-02-13 | 2014-10-28 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
| US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US8696719B2 (en) | 2010-06-03 | 2014-04-15 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3385040B2 (ja) * | 1991-02-14 | 2003-03-10 | 武田薬品工業株式会社 | グリア活性化因子およびその製造法 |
| WO2000054813A2 (en) | 1999-03-15 | 2000-09-21 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US7056885B1 (en) | 1999-07-27 | 2006-06-06 | Curagen Corporation | Fibroblast growth factor and nucleic acids encoding same |
| JP2003512841A (ja) | 1999-10-22 | 2003-04-08 | カイロン コーポレイション | ヒトおよびラットｆｇｆ−２０遺伝子および遺伝子発現産物 |
| WO2001068854A2 (en) | 2000-03-13 | 2001-09-20 | Amgen, Inc. | Fibroblast growth factor-like molecules and uses thereof |
| AU5056501A (en) | 2000-03-31 | 2001-10-08 | Nobuyuki Itoh | Fibroblast growth factor-like molecules and uses thereof |
| WO2001092522A2 (en) | 2000-06-01 | 2001-12-06 | Eli Lilly And Company | Human fgf-20 nucleic acids and polypeptides |
| JP2004502418A (ja) | 2000-07-03 | 2004-01-29 | キュラジェン コーポレイション | 新規の線維芽細胞増殖因子およびそれをコードする核酸 |
| AU2001292881A1 (en) | 2000-09-20 | 2002-04-02 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
-
2000
- 2000-07-03 US US09/609,543 patent/US7056885B1/en not_active Expired - Fee Related
- 2000-07-27 EP EP00952219A patent/EP1198563A2/en not_active Withdrawn
- 2000-07-27 JP JP2001512864A patent/JP2003505075A/ja active Pending
- 2000-07-27 CA CA002380226A patent/CA2380226A1/en not_active Abandoned
- 2000-07-27 AU AU64958/00A patent/AU781980B2/en not_active Ceased
- 2000-07-27 WO PCT/US2000/020405 patent/WO2001007595A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003505075A5 (enExample) | ||
| JP2005512515A5 (enExample) | ||
| Wallenius et al. | Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors | |
| US7674890B2 (en) | Stem cell factor-like proteins and uses thereof | |
| KR970707141A (ko) | 종양 괴사 인자-감마(Tumor necrosis factor-gamma) | |
| JPH0581569B2 (enExample) | ||
| JP2005505271A5 (enExample) | ||
| BR122016021558A2 (pt) | Polipeptídeos isolados, seus usos, e composição farmacêutica | |
| JP2000093186A (ja) | Ｆｒｉｚｚｌｅｄ―４ポリペプチドおよびＦｒｉｚｚｌｅｄ―４ポリヌクレオチド | |
| JP5856117B2 (ja) | 細胞シグナル伝達タンパク質ｎｅｌｌ１を用いた、創傷治癒及び筋再生の促進方法 | |
| JPH1175873A (ja) | 新規化合物 | |
| US20090118176A1 (en) | Stem Cell Factor-Like Protein Scfa1 and Uses Thereof | |
| JP2005528080A5 (enExample) | ||
| JP2004533235A5 (enExample) | ||
| KR101150900B1 (ko) | 퇴행성 관절염 치료 조성물 | |
| JP2005506833A5 (enExample) | ||
| JPH11253183A (ja) | Ｆｒｉｚｚｌｅｄ−３ポリペプチドおよびポリヌクレオチド | |
| WO2002030974A2 (en) | Proteins and nucleic acids encoding same | |
| JP2002300891A (ja) | 新規化合物 | |
| JP2004512310A (ja) | 新規用途 | |
| JP2005505247A5 (enExample) | ||
| JP2005504514A5 (enExample) | ||
| JP2005508157A5 (enExample) | ||
| JP2005507236A5 (enExample) | ||
| JP2005528886A5 (enExample) |